Two acute cas­es of liv­er dis­ease in healthy sub­jects kill Ar­bu­tus' hep B pro­gram

In a sig­nif­i­cant set­back, Vivek Ra­maswamy-backed Ar­bu­tus Bio­phar­ma is ceas­ing the de­vel­op­ment of its ex­per­i­men­tal he­pati­tis B ther­a­py, af­ter two healthy vol­un­teers con­tract­ed se­ri­ous liv­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER